Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

By sjmartinez • February 1, 2023

Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406. Epub ahead of print. PMID: 36720582.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology

Updated Psoriasis Prevalence and Risk Factors in the United States-Insights From the 2023 NHIS

Engel P, Wu JJ. Updated Psoriasis Prevalence and Risk Factors in the United States-Insights From the 2023 NHIS. Exp Dermatol. 2025 Aug;34(8):e70146. doi: 10.1111/exd.70146. PMID:[...]

Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of[...]

Novel Virtual Reality Intervention for Stress Reduction Among Patients With or at Risk for Cardiovascular Disease: Mixed Methods Pilot Study

Makaroff KE, Van C, Grospe V, Edmunds L, Calfon-Press MA, Watson KE, Horwich T. Novel Virtual Reality Intervention for Stress Reduction Among Patients With or[...]